US FDA commissioner's hammer falls on Avastin; breast cancer use revoked
This article was originally published in SRA
Executive Summary
US Food and Drug Administration commissioner Margaret Hamburg has rescinded the agency's approval for Genentech's Avastin (bevacizumab) as a treatment for HER2-negative metastatic breast cancer (MBC), after deciding that follow-up studies had failed to show that the drug is a safe and effective therapy for the disease1.